NASDAQ:BIB ProShares Ultra Nasdaq Biotechnology (BIB) Price, Holdings, & News $48.34 +0.43 (+0.90%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$46.86 -1.49 (-3.07%) As of 07/3/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIB alerts:Sign Up Key Stats Today's Range$47.95▼$48.4050-Day Range$39.63▼$48.3452-Week Range$33.78▼$69.56Volume4,898 shsAverage Volume11,268 shsMarket Capitalization$49.31 millionAssets Under Management$49.39 millionDividend Yield1.76%Net Expense Ratio0.95%Aggregate RatingModerate Buy ETF Overview ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Read More ProShares Ultra Nasdaq Biotechnology ExpensesTypeBIBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.56%0.56%0.54%0.53%Other Expenses0.39%0.47%0.56%0.52%0.56%Total Expense1.14%0.75%0.76%0.74%0.73%Fee Waiver-0.19%-0.67%-0.66%-0.50%-0.63%Net Expense0.95%0.60%0.63%0.63%0.60% Receive BIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares Ultra Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address BIB ETF News HeadlinesProShares Ultra Nasdaq Biotechnology declares quarterly distribution of $0.3964December 24, 2024 | msn.comProShares Ultra Nasdaq Biotechn (^BIB-IV)September 16, 2024 | ca.finance.yahoo.comTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House document might be the real trigger. One market expert who predicted major collapses in 2008 is now warning of a second, far more explosive directive tied to America’s most vital resource. If he’s right, it could set off a financial shock unlike anything we’ve seen in decades.July 6 at 2:00 AM | Porter & Company (Ad)ProShares Ultra Nasdaq BiotechnologyAugust 20, 2024 | morningstar.comMBio-Techne backs Harvard spinout making 'ultra-sensitive' blood testing techJuly 30, 2024 | bizjournals.comProShares Ultra Bloomberg Natural Gas: Trading Short-Term Tailwinds (Rating Upgrade)April 29, 2024 | seekingalpha.comSee More Headlines BIB ETF - Frequently Asked Questions How have BIB shares performed this year? ProShares Ultra Nasdaq Biotechnology's stock was trading at $50.66 on January 1st, 2025. Since then, BIB stock has decreased by 4.6% and is now trading at $48.34. How do I buy shares of ProShares Ultra Nasdaq Biotechnology? Shares of BIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares Ultra Nasdaq Biotechnology investors own include Westmoreland Coal (WLB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Salesforce (CRM). Fund Details IssuerProShares Fund NameProShares Ultra Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIB Inception Date4/6/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings290 Fund Statistics Assets Under Management$49.39 million Average Daily Volume$7.70 thousand Discount/Premium-0.08% Leveraged2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors, LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume2 Put Options49 Call Options2 Short Interest21,600 shs Miscellaneous Outstanding Shares1,020,000Beta1.63 Creation Unit50,000 Creation Fee$250.00 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report Top 10 BIB HoldingsNASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: 30.16%NASDAQ BIO INDEX SWAP BNP PARIBASHolding Weight: 26.09%NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: 19.09%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: 17.61%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: 17.61%NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONALHolding Weight: 17.39%Gilead Sciences (NASDAQ:GILD)Holding Weight: 5.57%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 5.53%Amgen (NASDAQ:AMGN)Holding Weight: 5.33%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 4.39%Full Holdings DetailsBIB Sector ExposureBIB Industry Exposure This page (NASDAQ:BIB) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.